Charles River Laboratories (NYSE: CRL) reported Q1 EPS of $1.29, $0.15 better than the analyst estimate of $1.14. Revenue for the quarter came in at $445.8 million versus the consensus estimate of $437.09 million.

GUIDANCE:

Charles River Laboratories sees FY2017 EPS of $5.00-$5.15, versus the consensus of $5.06.

• First-Quarter Revenue of $445.8 Million
• First-Quarter GAAP EPS of $0.97 and Non-GAAP EPS of $1.29

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.